Invex Therapeutics Stock Current Valuation
| IXC Stock | 0.07 0 4.29% |
Valuation analysis of Invex Therapeutics helps investors to measure Invex Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Cash is likely to drop to about 5.7 M in 2024. Cash And Short Term Investments is likely to drop to about 5.7 M in 2024. Fundamental drivers impacting Invex Therapeutics' valuation include:
Price Book 0.8852 | Enterprise Value -989.8 K | Enterprise Value Ebitda (1.33) | Price Sales 4.1537 |
Overvalued
Today
Please note that Invex Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Invex Therapeutics is based on 3 months time horizon. Increasing Invex Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Invex Therapeutics' intrinsic value may or may not be the same as its current market price of 0.07, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.067 | Real 0.0617 | Hype 0.07 | Naive 0.0633 |
The intrinsic value of Invex Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Invex Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Invex Therapeutics helps investors to forecast how Invex stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Invex Therapeutics more accurately as focusing exclusively on Invex Therapeutics' fundamentals will not take into account other important factors: Invex Therapeutics Company Current Valuation Analysis
Invex Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Invex Therapeutics Current Valuation | (989.76 K) |
Most of Invex Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Invex Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Invex Therapeutics has a Current Valuation of (989,761). This is much lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The current valuation for all Australia stocks is notably higher than that of the company.
Invex Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Invex Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Invex Therapeutics could also be used in its relative valuation, which is a method of valuing Invex Therapeutics by comparing valuation metrics of similar companies.Invex Therapeutics is currently under evaluation in current valuation category among its peers.
Invex Fundamentals
| Return On Equity | -0.12 | ||||
| Return On Asset | -0.0922 | ||||
| Profit Margin | (1.35) % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | (989.76 K) | ||||
| Shares Outstanding | 75.15 M | ||||
| Shares Owned By Insiders | 67.72 % | ||||
| Price To Book | 0.89 X | ||||
| Price To Sales | 4.15 X | ||||
| Revenue | 1.21 M | ||||
| Gross Profit | 459.08 K | ||||
| EBITDA | (720.44 K) | ||||
| Net Income | (1.64 M) | ||||
| Total Debt | 431.63 K | ||||
| Book Value Per Share | 0.08 X | ||||
| Cash Flow From Operations | (2.44 M) | ||||
| Earnings Per Share | (0.02) X | ||||
| Beta | 0.41 | ||||
| Market Capitalization | 5.04 M | ||||
| Total Asset | 6.12 M | ||||
| Retained Earnings | (19.22 M) | ||||
| Working Capital | 5.69 M | ||||
| Annual Yield | 2.78 % | ||||
| Net Asset | 6.12 M |
About Invex Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Invex Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Invex Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Invex Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Invex Stock Analysis
When running Invex Therapeutics' price analysis, check to measure Invex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Invex Therapeutics is operating at the current time. Most of Invex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Invex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Invex Therapeutics' price. Additionally, you may evaluate how the addition of Invex Therapeutics to your portfolios can decrease your overall portfolio volatility.